ArticleJournal of diabetes and metabolic disorders2026
Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis.
Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.Journal of diabetes and metabolic disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Tirzepatide, a dual agonist of the glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1R) receptors, has demonstrated efficacy in glycemic control and weight loss in patients with Type 2 diabetes mellitus (T2DM). Its role as adjunctive therapy in individuals with Type 1 diabetes mellitus (T1DM), particularly those who are overweight or obese, remains underexplored. This review aims to evaluate the efficacy of tirzepatide as an adjunct to insulin therapy in adults with Type 1 diabetes mellitus (T1DM) and overweight or obesity, focusing on changes in glycemic control, body weight, body mass index (BMI), and insulin dose requirements. Methods: A systematic review and meta-analysis, registered in PROSPERO (CRD42025633998), were conducted in accordance with PRISMA guidelines. Databases searched included PubMed, EMBASE, Web of Science, Scopus, and ClinicalTrials.gov. Risk of bias was assessed using ROBINS-I, and certainty of evidence was rated using GRADE. A random-effects model was applied. Results: Six observational studies, comprising 248 adults with Type 1 diabetes mellitus (T1DM) and overweight or obesity, were included. Tirzepatide adjunct therapy resulted in significant improvements across all major outcomes. HbA1c decreased by 0.61% [95% CI: - 0.69, - 0.52], body weight by 9.9 kg [95% CI: - 10.46, - 9.35], and BMI by 8.3 kg/m Conclusions: Tirzepatide adjunct therapy demonstrates meaningful improvements in glycemic control, weight, and insulin requirements among adults with T1DM and obesity, without major safety concerns. Despite promising findings, the evidence is limited by the observational design and overlapping patient cohorts. Larger randomized controlled trials are warranted to confirm these results and define optimal dosing and long-term safety. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-026-01880-0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.